Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Phase I study of copanlisib plus venetoclax in R/R DLBCLПодробнее

Results from a Phase I study of rapcabtagene autoleucel (YTB323), a novel CAR-T therapy in DLBCLПодробнее

Debate: How should patients with ABC type DLBCL be treated today? - R-CHOPПодробнее

The Next Phase of Targeted Therapy in MCL and DLBCLПодробнее

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell LymphomaПодробнее

Phase Ib/IIa study of AZD4573 and acalabrutinib in patients with R/R DLBCLПодробнее

Phase Ib/IIa study of AZD4573 and acalabrutinib in patients with R/R DLBCLПодробнее

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCLПодробнее

Phase II study of acalabrutinib plus RICE in R/R DLBCLПодробнее

Novel Treatment Combinations for R/R DLBCLПодробнее

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHLПодробнее

Interim analysis of anbal-cel for R/R DLBCLПодробнее

Dose-escalation results from Phase Ib/IIa trial of AZD4573 + acalabrutinib in R/R DLBCLПодробнее

Interim analysis of Phase II study of zamto-cel in R/R DLBCLПодробнее

The use of tafasitamab and lenalidomide in R/R DLBCLПодробнее

Update on Phase I study of plamotamab in R/R NHLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCLПодробнее

Addressing under-representation of elderly patients in DLBCL clinical trialsПодробнее